Yuya Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuya Ito has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Takayama
Department of Internal Medicine Takashima Municipal Hospital Takashima City Shiga Japan
1 shared publicationMakiko Kasahara
Department of Obstetrics and Gynecology Shiga University of Medical Science Otsu City Shiga Japan
1 shared publication- Shinsuke Tokoro
Department of Obstetrics and Gynecology, Shiga University of Medical Science, Otsu-City, Shiga Prefecture, Japan
1 shared publication - Shunichiro Tsuji
Department of Obstetrics and Gynecology, Shiga University of Medical Science, Shiga, Japan
1 shared publication Takashi Murakami
Department of Obstetrics and Gynecology Shiga University of Medical Science Otsu City Shiga Japan
1 shared publication
Latest Publications
- 24 October 2023
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (2) , 262-265
Successful perinatal management of a woman with congenital factor XIII deficiency using recombinant factor XIII: A case report and literature review
Factor XIII deficiency is an extremely rare autosomal recessive genetic disorder, occurring in 1 of 3–5 million people, and is associated with perinatal complications, such as habitual abortion and prolonged bleeding. Although plasma‐derived factor XIII (Fibrogamin®) carries a risk of infection and contains very low concentrated forms of factor XIII (FXIII) used for a pregnant woman with congenital coagulation factor XIII deficiency, recombinant factor XIII (rFXIII, Novo Thirteen®; Tretten®, Novo Nordisk, Bagsværd, Denmark), which has no risk of infection and is highly concentrated, has emerged as a novel formulation. Herein, we report the first case of a Japanese pregnant woman with congenital coagulation factor XIII deficiency successfully managed by rFXIII. She had a good perinatal course without pregnancy‐related complications and transfusion through the perinatal period.
- 24 October 2023
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (2) , 262-265
Successful perinatal management of a woman with congenital factor XIII deficiency using recombinant factor XIII: A case report and literature review
Factor XIII deficiency is an extremely rare autosomal recessive genetic disorder, occurring in 1 of 3–5 million people, and is associated with perinatal complications, such as habitual abortion and prolonged bleeding. Although plasma‐derived factor XIII (Fibrogamin®) carries a risk of infection and contains very low concentrated forms of factor XIII (FXIII) used for a pregnant woman with congenital coagulation factor XIII deficiency, recombinant factor XIII (rFXIII, Novo Thirteen®; Tretten®, Novo Nordisk, Bagsværd, Denmark), which has no risk of infection and is highly concentrated, has emerged as a novel formulation. Herein, we report the first case of a Japanese pregnant woman with congenital coagulation factor XIII deficiency successfully managed by rFXIII. She had a good perinatal course without pregnancy‐related complications and transfusion through the perinatal period.